Immunotherapies such as checkpoint inhibitors against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death-1 (PD-1)/PD ligand 1 (PD-L1) have represented a major advancement in the treatment of several types of solid tumour; however, these treatments have shown only very limited benefits in patients with GBM [7–9]. This evidence concerns the gene CTLA4 and glioblastoma.